{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T13:30:43Z","timestamp":1790775043275,"version":"4.1.0"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,5]],"date-time":"2023-06-05T00:00:00Z","timestamp":1685923200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thrombosisresearch.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.thromres.2023.06.001","type":"journal-article","created":{"date-parts":[[2023,6,5]],"date-time":"2023-06-05T11:27:48Z","timestamp":1685964468000},"page":"105-116","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Role of SHP2 (PTPN11) in glycoprotein VI-dependent thrombus formation: Improved platelet responsiveness by the allosteric drug SHP099 in Noonan syndrome patients"],"prefix":"10.1016","volume":"228","author":[{"given":"Delia I.","family":"Fern\u00e1ndez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marije","family":"Diender","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lidia","family":"Hermida-Nogueira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingnan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Veiras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvonne M.C.","family":"Henskens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maroeska W.M.","family":"te Loo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan W.M.","family":"Heemskerk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marijke J.E.","family":"Kuijpers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1ngel","family":"Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.thromres.2023.06.001_bb0005","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1093\/emboj\/16.9.2352","article-title":"Abnormal mesoderm patterning in mouse embryos mutant for the SH2 tyrosine phosphatase Shp2","volume":"16","author":"Saxton","year":"1997","journal-title":"EMBO J."},{"issue":"4","key":"10.1016\/j.thromres.2023.06.001_bb0010","doi-asserted-by":"crossref","first-page":"3066","DOI":"10.1021\/acs.jmedchem.1c02008","article-title":"Strategies targeting protein tyrosine phosphatase SHP2 for cancer therapy","volume":"65","author":"Song","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.thromres.2023.06.001_bb0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112117","article-title":"Therapeutic potential of targeting SHP2 in human developmental disorders and cancers","volume":"190","author":"Shen","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.thromres.2023.06.001_bb0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2019.104595","article-title":"Targeting SHP2 as a promising strategy for cancer immunotherapy","volume":"152","author":"Liu","year":"2020","journal-title":"Pharmacol. Res."},{"issue":"1","key":"10.1016\/j.thromres.2023.06.001_bb0025","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1111\/jth.14335","article-title":"Platelet Shp2 negatively regulates thrombus stability under high shear stress","volume":"17","author":"Hu","year":"2019","journal-title":"J. Thromb. Haemost."},{"issue":"3","key":"10.1016\/j.thromres.2023.06.001_bb0030","article-title":"The role of phospho-tyrosine signaling in platelet biology and hemostasis","volume":"1868","author":"Faria","year":"2021","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.thromres.2023.06.001_bb0035","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1182\/blood.2022017208","article-title":"More than reverting tyrosine kinases","volume":"140","author":"Heemskerk","year":"2022","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.thromres.2023.06.001_bb0040","doi-asserted-by":"crossref","first-page":"4205","DOI":"10.1182\/blood-2012-08-449272","article-title":"Megakaryocyte-specific deletion of the protein-tyrosine phosphatases Shp1 and Shp2 causes abnormal megakaryocyte development, platelet production, and function","volume":"121","author":"Mazharian","year":"2013","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.thromres.2023.06.001_bb0045","doi-asserted-by":"crossref","first-page":"2786","DOI":"10.1016\/j.bmc.2015.03.075","article-title":"Perspective: tyrosine phosphatases as novel targets for antiplatelet therapy","volume":"23","author":"Tautz","year":"2015","journal-title":"Bioorg. Med. Chem."},{"issue":"25","key":"10.1016\/j.thromres.2023.06.001_bb0050","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1182\/blood.2019001543","article-title":"Catalytic dysregulation of SHP2 leading to Noonan syndromes affects platelet signaling and functions","volume":"134","author":"Bellio","year":"2019","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.thromres.2023.06.001_bb0055","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1182\/blood-2008-06-165043","article-title":"CEACAM1 negatively regulates platelet-collagen interactions and thrombus growth in vitro and in vivo","volume":"113","author":"Wong","year":"2009","journal-title":"Blood"},{"issue":"248","key":"10.1016\/j.thromres.2023.06.001_bb0060","doi-asserted-by":"crossref","first-page":"ra78","DOI":"10.1126\/scisignal.2002936","article-title":"Mice lacking the ITIM-containing receptor G6b-B exhibit macrothrombocytopenia and aberrant platelet function","volume":"5","author":"Mazharian","year":"2012","journal-title":"Sci. Signal."},{"issue":"4","key":"10.1016\/j.thromres.2023.06.001_bb0065","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/ng772","article-title":"Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP2, cause Noonan syndrome","volume":"29","author":"Tartaglia","year":"2001","journal-title":"Nat. Genet."},{"issue":"5","key":"10.1016\/j.thromres.2023.06.001_bb0070","doi-asserted-by":"crossref","first-page":"e1299","DOI":"10.1542\/peds.2013-3251","article-title":"Hemostatic abnormalities in Noonan syndrome","volume":"133","author":"Artoni","year":"2014","journal-title":"Pediatrics"},{"issue":"2","key":"10.1016\/j.thromres.2023.06.001_bb0075","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/ng1156","article-title":"Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia","volume":"34","author":"Tartaglia","year":"2003","journal-title":"Nat. Genet."},{"issue":"24","key":"10.1016\/j.thromres.2023.06.001_bb0080","doi-asserted-by":"crossref","first-page":"8816","DOI":"10.1158\/0008-5472.CAN-04-1923","article-title":"Activating mutations of the Noonan syndrome-associated SHP2\/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia","volume":"64","author":"Bentires-Alj","year":"2004","journal-title":"Cancer Res."},{"issue":"17","key":"10.1016\/j.thromres.2023.06.001_bb0085","doi-asserted-by":"crossref","first-page":"7773","DOI":"10.1021\/acs.jmedchem.6b00680","article-title":"Allosteric inhibition of SHP2: identification of a potent, selective, and orally efficacious phosphatase inhibitor","volume":"59","author":"Garcia Fortanet","year":"2016","journal-title":"J. Med. Chem."},{"issue":"7610","key":"10.1016\/j.thromres.2023.06.001_bb0090","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/nature18621","article-title":"Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases","volume":"535","author":"Chen","year":"2016","journal-title":"Nature"},{"issue":"49","key":"10.1016\/j.thromres.2023.06.001_bb0095","doi-asserted-by":"crossref","first-page":"7166","DOI":"10.1038\/s41388-020-01488-5","article-title":"SHP2 is a multifunctional therapeutic target in drug resistant metastatic breast cancer","volume":"39","author":"Chen","year":"2020","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.thromres.2023.06.001_bb0100","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1158\/1078-0432.CCR-20-2718","article-title":"Combinations with allosteric SHP2 inhibitor TNO155 to block receptor tyrosine kinase signaling","volume":"27","author":"Liu","year":"2021","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.thromres.2023.06.001_bb0105","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1039\/D1MD00386K","article-title":"Recent advances in the discovery of protein tyrosine phosphatase SHP2 inhibitors","volume":"13","author":"Kong","year":"2022","journal-title":"RSC Med. Chem."},{"issue":"8","key":"10.1016\/j.thromres.2023.06.001_bb0110","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.1182\/blood-2003-01-0231","article-title":"GPVI levels in platelets: relationship to platelet function at high shear","volume":"102","author":"Best","year":"2003","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.thromres.2023.06.001_bb0115","doi-asserted-by":"crossref","first-page":"4162","DOI":"10.1182\/bloodadvances.2021006904","article-title":"GPVI expression is linked to platelet size, age, and reactivity","volume":"6","author":"Veninga","year":"2022","journal-title":"Blood Adv."},{"issue":"2","key":"10.1016\/j.thromres.2023.06.001_bb0120","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1055\/s-0039-3400295","article-title":"A comprehensive tyrosine phosphoproteomic analysis reveals novel components of the platelet CLEC-2 signaling cascade","volume":"120","author":"Izquierdo","year":"2020","journal-title":"Thromb. Haemost."},{"issue":"6","key":"10.1016\/j.thromres.2023.06.001_bb0125","doi-asserted-by":"crossref","first-page":"3440","DOI":"10.1016\/S0021-9258(19)83641-4","article-title":"A new generation of Ca2+ indicators with greatly improved fluorescence properties","volume":"260","author":"Grynkiewicz","year":"1985","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.thromres.2023.06.001_bb0130","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.3324\/haematol.2018.198853","article-title":"High-throughput elucidation of thrombus formation reveals sources of platelet function variability","volume":"104","author":"Van Geffen","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.thromres.2023.06.001_bb0135","doi-asserted-by":"crossref","first-page":"4257","DOI":"10.1038\/ncomms5257","article-title":"Identification of platelet function defects by multi-parameter assessment of thrombus formation","volume":"5","author":"De Witt","year":"2014","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.thromres.2023.06.001_bb0140","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1161\/ATVBAHA.115.306537","article-title":"Platelet control of fibrin distribution and microelasticity in thrombus formation under flow","volume":"36","author":"Swieringa","year":"2016","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.thromres.2023.06.001_bb0145","doi-asserted-by":"crossref","first-page":"8688","DOI":"10.3390\/ijms23158688","article-title":"Roles of focal adhesion kinase PTK2 and integrin aIIbb3 signaling in collagen- and GPVI-dependent thrombus formation under shear","volume":"23","author":"Huang","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"12","key":"10.1016\/j.thromres.2023.06.001_bb0150","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1161\/01.ATV.0000193568.71980.4a","article-title":"The glycoprotein VI-phospholipase Cgamma2 signaling pathway controls thrombus formation induced by collagen and tissue factor in vitro and in vivo","volume":"25","author":"Munnix","year":"2005","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"4","key":"10.1016\/j.thromres.2023.06.001_bb0155","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1002\/jha2.269","article-title":"Comparison of inhibitory effects of irreversible and reversible Btk inhibitors on platelet function","volume":"2","author":"Tullemans","year":"2021","journal-title":"EJHaem"},{"key":"10.1016\/j.thromres.2023.06.001_bb0160","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/ajmg.1320530213","article-title":"Clinical and molecular studies in a large Dutch family with Noonan syndrome","volume":"53","author":"Van den Burgt","year":"1994","journal-title":"Am. J. Med. Genet."},{"key":"10.1016\/j.thromres.2023.06.001_bb0165","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1750-1172-2-4","article-title":"Noonan syndrome","volume":"2","author":"Van der Burgt","year":"2007","journal-title":"Orphanet J. Rare Dis."},{"issue":"D1","key":"10.1016\/j.thromres.2023.06.001_bb0170","doi-asserted-by":"crossref","first-page":"D1062","DOI":"10.1093\/nar\/gkx1153","article-title":"ClinVar: improving access to variant interpretations and supporting evidence","volume":"46","author":"Landrum","year":"2018","journal-title":"Nucleic Acids Res."},{"issue":"2","key":"10.1016\/j.thromres.2023.06.001_bb0175","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1086\/499925","article-title":"Diversity and functional consequences of germline and somatic PTPN11 mutations in human disease","volume":"78","author":"Tartaglia","year":"2006","journal-title":"Am. J. Hum. Genet."},{"issue":"4","key":"10.1016\/j.thromres.2023.06.001_bb0180","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1007\/s10038-005-0239-7","article-title":"Functional analysis of PTPN11\/SHP-2 mutants identified in Noonan syndrome and childhood leukemia","volume":"50","author":"Niihori","year":"2005","journal-title":"J. Hum. Genet."},{"issue":"2","key":"10.1016\/j.thromres.2023.06.001_bb0185","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/sj.ejhg.5200935","article-title":"Spectrum of mutations in PTPN11 and genotype-phenotype correlation in 96 patients with Noonan syndrome and five patients with cardio-facio-cutaneous syndrome","volume":"11","author":"Musante","year":"2003","journal-title":"Eur. J. Hum. Genet."},{"issue":"1","key":"10.1016\/j.thromres.2023.06.001_bb0190","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s12881-020-0986-5","article-title":"Molecular and clinical studies in 107 Noonan syndrome affected individuals with PTPN11 mutations","volume":"21","author":"Athota","year":"2020","journal-title":"BMC Med. Genet."},{"issue":"3","key":"10.1016\/j.thromres.2023.06.001_bb0195","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/ajmg.a.30813","article-title":"Neurofibromatosis-Noonan syndrome: molecular evidence of the concurrence of both disorders in a patient","volume":"136","author":"Bertola","year":"2005","journal-title":"Am. J. Med. Genet. A"},{"key":"10.1016\/j.thromres.2023.06.001_bb0200","doi-asserted-by":"crossref","first-page":"11910","DOI":"10.1038\/s41598-020-68438-9","article-title":"Platelet-primed interactions of coagulation and anticoagulation pathways in flow-dependent thrombus formation","volume":"10","author":"Brouns","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.thromres.2023.06.001_bb0205","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1160\/TH13-06-0493","article-title":"Principal roles of platelets and fibrinogen in whole-blood fibrin clot formation in dilutional coagulopathy determined by thromboelastometry","volume":"111","author":"Ninivaggi","year":"2014","journal-title":"Thromb. Haemost."},{"issue":"19","key":"10.1016\/j.thromres.2023.06.001_bb0210","doi-asserted-by":"crossref","first-page":"3825","DOI":"10.2174\/1568011817666200928114851","article-title":"Allosteric inhibitors of SHP2: an updated patent review (2015-2020)","volume":"28","author":"Wu","year":"2021","journal-title":"Curr. Med. Chem."},{"issue":"1","key":"10.1016\/j.thromres.2023.06.001_bb0215","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.apsb.2020.07.010","article-title":"Tyrosine phosphatase SHP2 inhibitors in tumor-targeted therapies","volume":"11","author":"Song","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"issue":"Suppl. 15","key":"10.1016\/j.thromres.2023.06.001_bb0220","article-title":"Initial results from a dose finding study of TNO155, a SHP2 inhibitor, in adults with advanced solid tumors","volume":"39","author":"Brana","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.thromres.2023.06.001_bb0225","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1038\/s41467-017-02351-0","article-title":"Tyrosine phosphatase SHP2 negatively regulates NLRP3 inflammasome activation via ANT1-dependent mitochondrial homeostasis","volume":"8","author":"Guo","year":"2017","journal-title":"Nat. Commun."},{"issue":"6","key":"10.1016\/j.thromres.2023.06.001_bb0230","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1111\/cge.12568","article-title":"Malignancy in Noonan syndrome and related disorders","volume":"88","author":"Smpokou","year":"2015","journal-title":"Clin. Genet."},{"issue":"8","key":"10.1016\/j.thromres.2023.06.001_bb0235","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1002\/humu.20748","article-title":"The RAS\/MAPK syndromes: novel roles of the RAS pathway in human genetic disorders","volume":"29","author":"Aoki","year":"2008","journal-title":"Hum. Mutat."},{"issue":"8","key":"10.1016\/j.thromres.2023.06.001_bb0240","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1038\/ejhg.2011.37","article-title":"Cancer risk in patients with Noonan syndrome carrying a PTPN11 mutation","volume":"19","author":"Jongmans","year":"2011","journal-title":"Eur. J. Hum. Genet."},{"issue":"2","key":"10.1016\/j.thromres.2023.06.001_bb0245","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1182\/blood-2003-11-3876","article-title":"Genetic evidence for lineage-related and differentiation stage-related contribution of somatic PTPN11 mutations to leukemogenesis in childhood acute leukemia","volume":"104","author":"Tartaglia","year":"2004","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.thromres.2023.06.001_bb0250","doi-asserted-by":"crossref","first-page":"e83","DOI":"10.1158\/1078-0432.CCR-17-0631","article-title":"Recommendations for cancer surveillance in individuals with RASopathies and other rare genetic conditions with increased cancer risk","volume":"23","author":"Villani","year":"2017","journal-title":"Clin. Cancer Res."}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384823001731?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384823001731?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T17:51:21Z","timestamp":1758736281000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384823001731"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":50,"alternative-id":["S0049384823001731"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2023.06.001","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Role of SHP2 (PTPN11) in glycoprotein VI-dependent thrombus formation: Improved platelet responsiveness by the allosteric drug SHP099 in Noonan syndrome patients","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2023.06.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}